01 — Identity

What Is CJC-1295 with DAC?

2006

PUBLISHED

6–8 Days

HALF-LIFE

Albumin

DAC BINDS TO

Weekly

DOSING FREQ

Origin

Developed by ConjuChem Biotechnologies. The DAC (Drug Affinity Complex) technology uses a maleimidoproprionic acid-lysine linker that covalently binds to serum albumin after injection, dramatically extending half-life from minutes to 6–8 days.

Chemical Class

Tetrasubstituted GHRH analog with DAC modification. 30 amino acids. The albumin-binding linker is what separates this from CJC-1295 no DAC (Mod GRF 1-29).

Primary Use

Sustained GH elevation, body composition improvement, anti-aging. Weekly injection creates a persistent "GH wave" — continuous low-level GH support between natural pulses.

Administration

Subcutaneous injection. Once or twice weekly — the extended half-life makes daily injection unnecessary. Major adherence advantage over daily GHRH analogs.

DAC vs. no-DAC — key distinction: CJC-1295 with DAC creates a sustained GH "wave" — continuous low-level GH elevation that persists for nearly a week. CJC-1295 no DAC (Mod GRF 1-29) creates a sharp GH pulse that clears in 2–4 hours. These are fundamentally different pharmacokinetic profiles with different use cases. DAC = convenience and sustained elevation. No DAC = pulsatile, physiologic mimicry.

02 — Research History

Discovery & Research Timeline

1982

Native GHRH(1-44) sequenced. Early analogs show potential but are limited by ultra-short plasma half-life (~2 minutes) due to DPP-IV protease cleavage. Stability engineering becomes the primary development challenge.

2000–2004

ConjuChem Biotechnologies develops the DAC (Drug Affinity Complex) platform — a maleimidoproprionic acid linker that covalently binds peptides to serum albumin after injection. Albumin binding confers a half-life matching albumin's own ~19-day half-life, extended in practice by the binding kinetics to 6–8 days for CJC-1295 with DAC.

2006

Landmark human study published: "Long-acting growth hormone–releasing factor can reverse somatopause." CJC-1295 with DAC at 2mg doses showed 2–10× increases in serum GH AUC and proportional IGF-1 increases lasting 6–8 days per injection. Confirmed sustained GH elevation with excellent tolerability.

2008–Present

Despite promising human data, ConjuChem halts clinical development due to financial constraints — not safety concerns. CJC-1295 with DAC enters the research peptide market and becomes widely used in anti-aging and performance optimization communities for its convenient weekly dosing and sustained GH elevation.

03 — Primary Benefits

Documented Effects

01

Sustained GH Elevation

The 6–8 day half-life creates a continuous low-level GH "wave" between pulses. Unlike daily GHRH analogs that produce sharp nightly pulses, CJC-1295 DAC maintains GH elevation throughout the week — a distinct pharmacokinetic profile with different body composition implications.

02

Weekly Convenience

Once-weekly injection replaces daily nightly injections required for Sermorelin, Tesamorelin, or CJC-1295 no DAC. Major adherence advantage — users are significantly more likely to maintain a weekly protocol vs. daily nightly injections over months.

03

IGF-1 Increase

Published human data showed proportional IGF-1 increases lasting the full 6–8 days. 2–10× GH AUC increase translates to meaningful, sustained IGF-1 elevation driving body composition and tissue repair effects.

04

Body Composition

Sustained GH/IGF-1 elevation promotes fat loss and lean mass accretion over 12–24 week cycles. The continuous GH signal supports lipolysis around the clock rather than only during the nocturnal pulse window.

05

Anti-Aging Support

GH/IGF-1 axis supports collagen synthesis, skin elasticity, bone density, and cognitive function. Sustained elevation via DAC technology provides consistent anti-aging signaling without the peaks and troughs of daily protocols.

06

Sleep Quality

While the GH pulse is not synchronized to sleep onset (as with nightly GHRH analogs), sustained low-level GH elevation still supports overall sleep architecture improvement over weeks of consistent use.

04 — Reconstitution

Mixing & Storage

▸ Standard Reconstitution — 5mg Vial

5mg vial + 300 units BAC water = 16.7 mcg per unit on insulin syringe

5,000 mcg total per vial · Refrigerate after reconstitution · Use within 4–6 weeks · Protect from light

DOSE REFERENCE TABLE

DOSE	DRAW (5mg vial)	FREQUENCY
250mcg	~15 units	Once weekly
500mcg	~30 units	Once weekly (most common)
1000mcg	~60 units	Once weekly (upper range)

UNRECONSTITUTED

Refrigerate at 36–46°F / 2–8°C. Stable at room temp for shipping. Do not freeze lyophilized powder.

RECONSTITUTED

Refrigerate at 36–46°F / 2–8°C. Use within 4–6 weeks. Keep away from light. Do not freeze.

05 — Dosing Protocol

Dose Levels & Unit Draws

Level	Dose	Syringe Draw	Description
LOW	250mcg ~15 units on insulin syringe	~15u	Conservative weekly dose. Good for users new to GHRH analogs or those sensitive to GH-related side effects (fluid retention, joint discomfort).
STANDARD	500mcg ~30 units on insulin syringe	~30u	Most commonly used weekly dose. Matches the lower end of published human study dosing. Best balance of efficacy and tolerability for most users.
HIGH	1000mcg ~60 units on insulin syringe	~60u	Upper range. Used in published human studies. Monitor for GH-related side effects at this dose — fluid retention and joint discomfort are more common. Monitor glucose.

Some users split the weekly dose into 2 injections (e.g., 500mcg × 2 = 1000mcg/week) administered on Monday and Thursday. This maintains more consistent week-to-week GH levels and may reduce side effects by avoiding a single large weekly peak. Either approach is valid.

06 — Timing & Frequency

When & How Often

Variable	Recommendation	Why
Frequency	Once weekly (or 2× weekly)	The 6–8 day half-life means a single weekly injection maintains continuous GH elevation. 2× weekly splits the dose for smoother week-over-week levels.
Time of Day	Any time — less critical than no-DAC	Unlike nightly GHRH analogs that synchronize with sleep, CJC-1295 DAC creates continuous elevation regardless of when it's injected. Morning or evening both work.
Fed State	Fasted preferred — not critical	Fasted preferred to maximize the initial GH pulse at injection. Given the sustained release mechanism, food timing is less critical than with short-acting GHRH analogs.
Stack Compatibility	+ Ipamorelin at weekly injection	Many users add Ipamorelin at the weekly injection site to amplify the initial GH pulse via the GHRP pathway. The CJC-1295 DAC then maintains the baseline elevation for the week.

07 — Biomarker Monitoring

Lab Tests & Optimal Ranges

▸ GH Axis Efficacy

Biomarker	Lab Test	Clinical Range	Optimal Range
IGF-1	Serum IGF-1	CLINICALAge-dependent	OPTIMALUpper third of age range
IGFBP-3	Serum IGFBP-3	CLINICALAge-dependent	OPTIMALUpper third of age range
Fasting Glucose	Fasting plasma glucose	CLINICAL70–100 mg/dL	OPTIMAL75–90 mg/dL
Fasting Insulin	Serum insulin	CLINICAL2–25 µIU/mL	OPTIMAL2–6 µIU/mL
HbA1c	Hemoglobin A1c	CLINICAL<5.7%	OPTIMAL4.6–5.3%
AST / ALT	CMP	CLINICALAST 10–40 / ALT 7–56 U/L	OPTIMALAST <26 / ALT <26 U/L
CBC	Complete Blood Count	CLINICALStandard ranges	OPTIMALMid-range

READY TO ADD THIS TO YOUR STACK?

Drop CJC-1295 DAC into your protocol tracker — dosing pre-filled, timing set, cycle ready.

ADD TO MY PROTOCOL →

Saves your dose selection. Returns you here after.

⚠ CJC-1295 with DAC is not FDA-approved. Human data from a 2006 publication — no subsequent large clinical trials. The sustained GH elevation created by the DAC mechanism is pharmacologically different from pulsatile GH release — long-term implications of continuous vs. pulsatile GH elevation are not fully characterized. Monitor glucose metabolism carefully. Do not use in active malignancy.

08 — Cycle Protocol

Cycle Length, Frequency & Timing

STANDARD CYCLE

12–24 Weeks

Once weekly at 500mcg–1mg. IGF-1 measurably rises within 2–4 weeks. Full body composition effects at 12–24 weeks of consistent use.

BREAK

4–8 Weeks

Allow pituitary receptor recovery. Given the longer cycle duration enabled by weekly dosing, breaks may be less frequent than daily GHRH protocols.

PROTOCOL SUMMARY

12–24 wk

CYCLE LENGTH

1–2×/wk

FREQUENCY

Any

TIME OF DAY

Fasted pref

FED STATE

4–8 wk

BREAK

SC

ROUTE